Real-World data on nivolumab for stomach cancer: what happened?
NCT ID NCT06452329
First seen Jan 11, 2026 · Last updated May 18, 2026 · Updated 19 times
Summary
This study looked back at medical records of 260 adults in China with advanced stomach or gastroesophageal junction cancer. All patients received nivolumab as their first treatment. The goal was to see how well the drug worked in real life and how it was used. This was an observational study, not a trial testing a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Local Institution - 0001
Wuhan, Hubei, 430030, China
-
Tianjin Happy Life Technology Co., Ltd
Shanghai, China
Conditions
Explore the condition pages connected to this study.